OBJECTIVE: The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established. We examined this issue in the Danish Diet, Cancer, and Health Study. METHODS: Self-reported NSAID use at entry (January 1995-May 1997) was updated through June 2006, using a nationwide prescription database. CRC incidence was ascertained from nationwide registers. Cox proportional hazards regression was used to compute confounder-adjusted incidence rate ratios (RRs) and 95% confidence intervals (CIs). RESULTS: From 51,053 cohort subjects, we identified 615 CRC cases during 1995-2006. Daily aspirin use at entry was associated with a decreased risk of CRC (RR, 0.73; 95% CI, 0.49-1.10). A similar risk reduction was seen among subjects with 10 or more prescriptions for aspirin or non-aspirin NSAIDs and five or more years of follow-up. Most aspirin prescriptions were for 75-150 mg aspirin tablets. Among non-aspirin NSAID users, only those with body mass index (BMI) above 25 showed risk reductions [RR, 0.69 (0.47-1.03) for 10 or more prescriptions]. CONCLUSIONS: Long-term consistent use of aspirin or non-aspirin NSAIDs appears necessary to achieve a protective effect against CRC. Further studies of the effective dose of aspirin and the potential interaction between NSAID use and BMI are warranted.
OBJECTIVE: The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established. We examined this issue in the Danish Diet, Cancer, and Health Study. METHODS: Self-reported NSAID use at entry (January 1995-May 1997) was updated through June 2006, using a nationwide prescription database. CRC incidence was ascertained from nationwide registers. Cox proportional hazards regression was used to compute confounder-adjusted incidence rate ratios (RRs) and 95% confidence intervals (CIs). RESULTS: From 51,053 cohort subjects, we identified 615 CRC cases during 1995-2006. Daily aspirin use at entry was associated with a decreased risk of CRC (RR, 0.73; 95% CI, 0.49-1.10). A similar risk reduction was seen among subjects with 10 or more prescriptions for aspirin or non-aspirin NSAIDs and five or more years of follow-up. Most aspirin prescriptions were for 75-150 mg aspirin tablets. Among non-aspirin NSAID users, only those with body mass index (BMI) above 25 showed risk reductions [RR, 0.69 (0.47-1.03) for 10 or more prescriptions]. CONCLUSIONS: Long-term consistent use of aspirin or non-aspirin NSAIDs appears necessary to achieve a protective effect against CRC. Further studies of the effective dose of aspirin and the potential interaction between NSAID use and BMI are warranted.
Authors: Xinwei Hua; Amanda I Phipps; Andrea N Burnett-Hartman; Scott V Adams; Sheetal Hardikar; Stacey A Cohen; Jonathan M Kocarnik; Dennis J Ahnen; Noralane M Lindor; John A Baron; Polly A Newcomb Journal: J Clin Oncol Date: 2017-06-15 Impact factor: 44.544
Authors: Xiaoliang Wang; Andrew T Chan; Martha L Slattery; Jenny Chang-Claude; John D Potter; Steven Gallinger; Bette Caan; Johanna W Lampe; Polly A Newcomb; Niha Zubair; Li Hsu; Robert E Schoen; Michael Hoffmeister; Hermann Brenner; Loic Le Marchand; Ulrike Peters; Emily White Journal: Cancer Res Date: 2018-06-19 Impact factor: 12.701
Authors: Xuehong Zhang; Stephanie A Smith-Warner; Andrew T Chan; Kana Wu; Donna Spiegelman; Charles S Fuchs; Walter C Willett; Edward L Giovannucci Journal: Am J Epidemiol Date: 2011-06-14 Impact factor: 4.897
Authors: Hongmei Nan; Carolyn M Hutter; Yi Lin; Eric J Jacobs; Cornelia M Ulrich; Emily White; John A Baron; Sonja I Berndt; Hermann Brenner; Katja Butterbach; Bette J Caan; Peter T Campbell; Christopher S Carlson; Graham Casey; Jenny Chang-Claude; Stephen J Chanock; Michelle Cotterchio; David Duggan; Jane C Figueiredo; Charles S Fuchs; Edward L Giovannucci; Jian Gong; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Mark A Jenkins; Shuo Jiao; Noralane M Lindor; Mathieu Lemire; Loic Le Marchand; Polly A Newcomb; Shuji Ogino; Bethann M Pflugeisen; John D Potter; Conghui Qu; Stephanie A Rosse; Anja Rudolph; Robert E Schoen; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Stephen N Thibodeau; Fridtjof Thomas; Mark Thornquist; Greg S Warnick; Brent W Zanke; W James Gauderman; Ulrike Peters; Li Hsu; Andrew T Chan Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Hongmei Nan; Teppei Morikawa; Miia Suuriniemi; Yu Imamura; Lillian Werner; Aya Kuchiba; Mai Yamauchi; David J Hunter; Peter Kraft; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino; Matthew L Freedman; Andrew T Chan Journal: J Natl Cancer Inst Date: 2013-12-07 Impact factor: 13.506